Analyst Ratings For Hikma Pharmaceuticals Plc (LON:HIK)
Today, Hikma Pharmaceuticals Plc (LON:HIK) stock was downgraded by Morgan Stanley from Equal weight to with a price target of GBX 1,600.
There are 2 sell ratings, 4 hold ratings, 4 buy ratings on the stock.
The current consensus rating on Hikma Pharmaceuticals Plc (LON:HIK) is Hold (Score: 2.20) with a consensus target price of GBX 1,936.10 per share, a potential .
Some recent analyst ratings include
- 8/2/2017-Morgan Stanley was Downgraded by analysts at Morgan Stanley from a “Equal weight” rating to a “” rating. They now have a GBX 1,600 price target on the stock, up previously from GBX 2,050 .
- 7/4/2017-HSBC Holdings plc Reiterated Rating of Reduce.
- 7/3/2017-Barclays PLC Reiterated Rating of Overweight.
- 6/28/2017-Citigroup Inc. Reiterated Rating of Neutral.
- 6/27/2017-J P Morgan Chase & Co Reiterated Rating of Neutral.
- 5/19/2017-Numis Securities Ltd Reiterated Rating of Add.
Recent Trading Activity for Hikma Pharmaceuticals Plc (LON:HIK)
Shares of Hikma Pharmaceuticals Plc closed the previous trading session at 1,406.00 down -24.00 -1.68% with 481,283 shares trading hands.
